open access

Vol 91, No 5 (2020)
Clinical vignette
Published online: 2020-05-29
Get Citation

Right-sided ovarian ectopic pregnancy with Jaydess in situ

Lukasz Panasowiec1, Maja Kufelnicka-Babout1, Piotr Sieroszewski1
DOI: 10.5603/GP.2020.0059
·
Pubmed: 32495937
·
Ginekol Pol 2020;91(5):294.
Affiliations
  1. Fetal Medicine and Gynecology Department, Medical University of Lodz, Poland

open access

Vol 91, No 5 (2020)
CLINICAL VIGNETTES
Published online: 2020-05-29

Abstract

The estimated prevalence of the ectopic pregnancy (EP) is 1–2% of all pregnancies. Ovarian pregnancy is a rare finding with
an incidence rate of 0.15% of all pregnancies and 1–3% of ectopic gestations. The use of intrauterine device (IUD) is a significant
risk factor of ectopic pregnancy. Jaydess levonorgestrel intrauterine system (LNG-IUS) is considered as an extremely
reliable method of contraception with the cumulative Pearl index of approx. 0.9% after a three-year period of use. This study
presents a case of failure of the Jaydess intrauterine device in situ in a female patient with positive Beta Human Chorionic
Gonadotropin (serum b-HCG) who was diagnosed with right-sided ovarian ectopic pregnancy. Although LNG-IUS represents
the group of the most efficient contraception methods, the risks of failure still exist and should be taken into consideration.
Before the insertion, every female patient should be fully informed on the potential adverse effects by a health practitioner.

Abstract

The estimated prevalence of the ectopic pregnancy (EP) is 1–2% of all pregnancies. Ovarian pregnancy is a rare finding with
an incidence rate of 0.15% of all pregnancies and 1–3% of ectopic gestations. The use of intrauterine device (IUD) is a significant
risk factor of ectopic pregnancy. Jaydess levonorgestrel intrauterine system (LNG-IUS) is considered as an extremely
reliable method of contraception with the cumulative Pearl index of approx. 0.9% after a three-year period of use. This study
presents a case of failure of the Jaydess intrauterine device in situ in a female patient with positive Beta Human Chorionic
Gonadotropin (serum b-HCG) who was diagnosed with right-sided ovarian ectopic pregnancy. Although LNG-IUS represents
the group of the most efficient contraception methods, the risks of failure still exist and should be taken into consideration.
Before the insertion, every female patient should be fully informed on the potential adverse effects by a health practitioner.

Get Citation

Keywords

ovarian ectopic pregnancy; contraception; intrauterine device failure; Jaydess levonorgestrel intrauterine system; life-threatening hemorrhage; natural conception

About this article
Title

Right-sided ovarian ectopic pregnancy with Jaydess in situ

Journal

Ginekologia Polska

Issue

Vol 91, No 5 (2020)

Article type

Clinical vignette

Pages

294

Published online

2020-05-29

DOI

10.5603/GP.2020.0059

Pubmed

32495937

Bibliographic record

Ginekol Pol 2020;91(5):294.

Keywords

ovarian ectopic pregnancy
contraception
intrauterine device failure
Jaydess levonorgestrel intrauterine system
life-threatening hemorrhage
natural conception

Authors

Lukasz Panasowiec
Maja Kufelnicka-Babout
Piotr Sieroszewski

References (5)
  1. Shrestha A, Chawla CD, Shrestha RM. Ruptured Primary Ovarian Pregnancy: A Rare Case Report. Kathmandu University Medical Journal. 2013; 10(3): 76–77.
  2. Sergent F, Mauger-Tinlot F, Gravier A, et al. Grossesses ovariennes: réévaluation des critères diagnostiques. J Gynecol Obstet Biol Reprod (Paris. 2002; 31: 741–746.
  3. Gaudoin MR, Coulter KL, Robins AM, et al. Is the incidence of ovarian ectopic pregnancy increasing? European Journal of Obstetrics & Gynecology and Reproductive Biology. 1996; 70(2): 141–143.
  4. Raziel A, Golan A, Pansky M, et al. Ovarian pregnancy: A report of twenty cases in one institution. American Journal of Obstetrics and Gynecology. 1990; 163(4): 1182–1185.
  5. Herbertsson G, Magnusson S, Benediktsdottir K. Ovarian pregnancy and iucd use in a defined complete population. Acta Obstetricia et Gynecologica Scandinavica. 1987; 66(7): 607–610.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl